BACKGROUND:Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil.
OBJECTIVES:The objective of this review was to assess the effects of Nicobrevin on long term smoking cessation
SEARCH STRATEGY:We searched the Cochrane Tobacco Addiction Group trials register.
SELECTION CRITERIA:Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up.
DATA COLLECTION AND ANALYSIS:Data were sought on the outcome, method of randomization, and completeness of follow up.
MAIN RESULTS:We identified no trials meeting the full inclusion criteria including long-term follow up.
AUTHORS' CONCLUSIONS:There is no evidence available from long-term trials that Nicobrevin can aid smoking cessation.